FDA Inspection 1102732 — Novum Pharma, LLC

Novum Pharma, LLC — FEI 3013162819

The FDA completed an inspection of Novum Pharma, LLC on September 24, 2019 in Chicago, IL. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 8 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
September 24, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Chicago, IL (United States)

Citations

IDCFRDescription
107921 CFR 211.22(a)Contract drug products--lack of responsibility
110521 CFR 211.22(d)Procedures not in writing, fully followed
192621 CFR 211.166(b)Adequate number of batches on stability
202621 CFR 211.192Quality control unit review of records
202721 CFR 211.192Investigations of discrepancies, failures
438921 CFR 211.198(a)Procedures to be written and followed
439121 CFR 211.180(e)(2)Items to cover on annual reviews
670921 CFR 310.305(c)(2)Investigation of serious, unexpected events